Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26, CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy, setting a price target of $835.00.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.

The company also increased the midpoint of its 2025 full-year revenue guidance by $1.5 billion to be in the $60 billion to $62 billion range, with reported EPS guidance raised to be in the range of $20.85 to $22.10.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.